Pipobroman is a synthetic antineoplastic active pharmaceutical ingredient (API) belonging to the class of alkylating agents. Chemically, it is an N-acylpiperazine derivative containing two 3-bromopropionyl groups. Its chemical name is 1,4-Bis(3-bromopropionyl)piperazine. Pipobroman is associated with antineoplastic activity and has been used clinically in the management of certain myeloproliferative disorders.
Pipobroman has the molecular formula C₁₀H₁₆Br₂N₂O₂, molecular weight 356.05 g/mol, and CAS Number 54-91-1. The substance is achiral and has no defined stereocenters.
Pipobroman is available as a pharmaceutical and analytical active substance for applications involving antineoplastic research and pharmaceutical development. It is also known by synonyms including 1,4-Bis(3-bromopropionyl)piperazine, N,N-Bis(3-bromopropionyl)piperazine, and NSC-25154.
The substance is described in established chemical references as a white or practically white crystalline powder. Commercial analytical material is also described as a white-to-beige powder.
Pipobroman is an antineoplastic alkylating agent. FDA's substance database classifies it under antineoplastic agents and alkylating agents, while WHO ATC classification places it under L01AX02 — Other alkylating agents.
Historically, pipobroman has been used in the treatment of conditions including polycythemia vera and essential thrombocythemia.
Pipobroman API can be characterized using appropriate analytical procedures including chromatographic purity testing and spectroscopic identification. Commercial analytical-grade material is available with ≥98% HPLC assay, while a representative Certificate of Analysis reports >98.0% HPLC purity together with NMR and mass-spectrometric confirmation. These values should be treated as product-specific analytical specifications, not as a universal pharmacopoeial release standard.
For pharmaceutical API applications, quality evaluation may include identity, assay/purity, related substances, residual solvents, water content, inorganic impurities and other parameters defined by the applicable approved specification.
Pipobroman API intended for pharmaceutical applications should be manufactured and tested under appropriate pharmaceutical quality systems with controlled raw materials, validated analytical procedures and documented batch release requirements.
For commercial pharmaceutical requirements, customers can request the applicable Certificate of Analysis (CoA), product specification, analytical documentation, regulatory documentation and technical information for Pipobroman API.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 0.5% |